Shattuck Labs Inc (STTK) Stock Price, Quote & News

Company Profile

Shattuck Labs, Inc., a biotechnology company, develops antibodies for the treatment of inflammatory and immune-mediated diseases. The company's lead product candidate includes SL-325, a DR3 blocking monoclonal antibody, which activates immune responses through binding a single receptor, DR3; and SL-425. It also develops multiple preclinical DR3-based bispecific antibodies for the treatment of inflammatory bowel disease; and a series of bispecific antibodies targeting DR3 and other clinically val...

Industry: Biotechnology

Sector: Healthcare

Phone: 512 900 4690

Website: www.shattucklabs.com

Address:

500 West 5th Street, Suite 1200, Austin, United States

Doozio Dec. 5 at 2:45 AM

$STTK bahhht this cycle is 🐒🍌🧠⏰♾️

1 · Reply

Iightning Dec. 5 at 12:37 AM

1ightning® Premium Options Alert (Actionable) Ticker: $STTK Contract: Dec 19 $2.5C Entry: 0.62 Exit: 0.77 Return: +23.43% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

NyseDayTrader Dec. 4 at 3:21 PM

$STTK Oh how i spited my face!!! i saw the accumlation occurring. Still have 10k though

0 · Reply

hitmongreen Dec. 2 at 8:50 PM

$STTK 🤔

0 · Reply

Iightning Dec. 2 at 2:53 AM

**1ightning® Premium Options Alert (Actionable)** **Ticker:** $STTK **Contract:** Dec 19 $2.5C **Entry:** 1.16 **Exit:** 2.23 **Return:** **+91.85% ROI** This is the level of accuracy our VIP desk delivers daily. If you want **institutional-grade scalps without the noise**, join us. **Unlock VIP Access → https://1ightning.com**

0 · Reply

topstockalerts Dec. 1 at 11:55 PM

Top Gainers PT2 $IVDA $MAIA $AGRZ $STTK $AGCC

0 · Reply

topstockalerts Dec. 1 at 9:10 PM

Top Gainers PT2 $IVDA $MAIA $AGRZ $STTK $AGCC

0 · Reply

_www_larval_com_ Dec. 1 at 5:33 PM

$STTK has turned -5% lower to 10% (~778Kv) moments ago, 12/19 options, follow for more volatility.

0 · Reply

topstockalerts Dec. 1 at 5:26 PM

Top Gainers PT2 $IVDA $MAIA $AGRZ $STTK $AGCC

0 · Reply

DARKP00L Dec. 1 at 5:18 PM

$STTK 12:01 on Dec. 01 2025 Shattuck Labs shares are trading higher after HC Wainwright & Co upgraded the stock from Neutral to Buy and announced a $6 price target. #tradeideas

0 · Reply

Analyst Upgrade Boosts Shattuck On Confidence In Next-Gen Inflammatory Bowel Disease Therapy

Nov 20, 2025, 8:00 AM EST - 14 days ago

Shattuck Labs to Participate in Upcoming December Investor Conferences

Nov 6, 2025, 4:30 PM EST - 4 weeks ago

Shattuck Labs Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Oct 10, 2025, 9:16 PM EDT - 7 weeks ago

Shattuck Labs, Inc. (STTK) Presents at The United European Gastroenterology (UEG) Congress UEG Week 2025 Transcript

Oct 2, 2025, 7:51 AM EDT - 2 months ago

Shattuck Labs Announces Participation in Upcoming Wedbush Securities Key Opinion Leader (KOL) and Company Panel

Aug 26, 2025, 6:30 AM EDT - 3 months ago

Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors

Aug 21, 2025, 10:17 AM EDT - 3 months ago

Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease

Aug 14, 2025, 6:30 AM EDT - 4 months ago

Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 5, 2025, 6:30 AM EDT - 4 months ago

Shattuck Labs Announces Oversubscribed Private Placement of Up to Approximately $103 Million

Jul 2, 2025, 7:00 AM EDT - 5 months ago

Shattuck Labs Announces Participation in Upcoming Leerink Partners Therapeutics Forum: I&I and Metabolism

May 1, 2025, 4:20 PM EDT - 7 months ago

Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights

Apr 2, 2025, 5:00 PM EDT - 8 months ago

Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference

Mar 27, 2025, 7:00 AM EDT - 9 months ago

Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

Feb 20, 2025, 9:00 AM EST - 10 months ago

Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025

Feb 13, 2025, 4:30 PM EST - 10 months ago

Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025

Feb 4, 2025, 7:00 AM EST - 10 months ago

Shattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn's and Colitis Congress

Jan 6, 2025, 4:59 PM EST - 11 months ago

Shattuck Labs Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 2, 2025, 7:00 AM EST - 1 year ago

Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2025

Oct 29, 2024, 10:00 AM EDT - 1 year ago

Shattuck Labs, Inc. (STTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Oct 28, 2024, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Encourages Shattuck Labs, Inc. (STTK) Shareholders to Inquire about Securities Investigation

Oct 27, 2024, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Shattuck Labs, Inc. (STTK) And Encourages Shareholders to Connect

Oct 23, 2024, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Shattuck Labs, Inc. (STTK) And Encourages Investors to Connect

Oct 22, 2024, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Encourages Shattuck Labs, Inc. (STTK) Stockholders to Inquire about Securities Investigation

Oct 21, 2024, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Shattuck Labs, Inc. (STTK) and Encourages Investors to Learn More About the Investigation

Oct 20, 2024, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Shattuck Labs, Inc. (STTK) And Encourages Stockholders to Connect

Oct 16, 2024, 10:00 AM EDT - 1 year ago

Shattuck Labs, Inc. (STTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Oct 15, 2024, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Shattuck Labs, Inc. (STTK) and Encourages Stockholders to Learn More About the Investigation

Oct 14, 2024, 6:00 PM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Encourages Shattuck Labs, Inc. (STTK) Investors to Inquire about Securities Investigation

Oct 1, 2024, 12:23 PM EDT - 1 year ago

Shattuck Labs' stock craters as biotech scraps main product candidate after failed trial

Oct 1, 2024, 6:30 AM EDT - 1 year ago

Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway

Jul 30, 2024, 5:00 PM EDT - 1 year ago

Shattuck Labs Announces Participation in Upcoming BTIG Virtual Biotechnology Conference

Jul 1, 2024, 6:00 AM EDT - 1 year ago

Shattuck Labs Announces Addition to Russell 2000® and Russell 3000® Indexes

Jun 14, 2024, 6:00 AM EDT - 1 year ago

Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leuk

Jun 10, 2024, 7:30 AM EDT - 1 year ago

Shattuck Labs Announces Orphan Drug Designation Granted by the U.S. Food and Drug Administration (FDA) for SL-172154 for the Treatment of Acute Myeloid Leukemia (AML)

Jun 6, 2024, 7:30 AM EDT - 1 year ago

Shattuck Labs to Host Investor Call and Webcast on Additional Interim Data Presented at the European Hematology Association (EHA) 2024 Congress from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk My

May 14, 2024, 4:15 PM EDT - 1 year ago

Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients at the E

May 2, 2024, 7:05 AM EDT - 1 year ago

Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights

Apr 9, 2024, 4:05 PM EDT - 1 year ago

Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024

Apr 1, 2024, 7:00 AM EDT - 1 year ago

Shattuck Labs Announces Participation in Upcoming 23rd Annual Needham Virtual Healthcare Conference

Mar 4, 2024, 7:00 AM EST - 1 year ago

Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D.

Feb 29, 2024, 4:05 PM EST - 1 year ago

Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights

Doozio Dec. 5 at 2:45 AM

$STTK bahhht this cycle is 🐒🍌🧠⏰♾️

1 · Reply

Iightning Dec. 5 at 12:37 AM

1ightning® Premium Options Alert (Actionable) Ticker: $STTK Contract: Dec 19 $2.5C Entry: 0.62 Exit: 0.77 Return: +23.43% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

NyseDayTrader Dec. 4 at 3:21 PM

$STTK Oh how i spited my face!!! i saw the accumlation occurring. Still have 10k though

0 · Reply

hitmongreen Dec. 2 at 8:50 PM

$STTK 🤔

0 · Reply

Iightning Dec. 2 at 2:53 AM

0 · Reply

topstockalerts Dec. 1 at 11:55 PM

Top Gainers PT2 $IVDA $MAIA $AGRZ $STTK $AGCC

0 · Reply

topstockalerts Dec. 1 at 9:10 PM

Top Gainers PT2 $IVDA $MAIA $AGRZ $STTK $AGCC

0 · Reply

_www_larval_com_ Dec. 1 at 5:33 PM

$STTK has turned -5% lower to 10% (~778Kv) moments ago, 12/19 options, follow for more volatility.

0 · Reply

topstockalerts Dec. 1 at 5:26 PM

Top Gainers PT2 $IVDA $MAIA $AGRZ $STTK $AGCC

0 · Reply

DARKP00L Dec. 1 at 5:18 PM

$STTK 12:01 on Dec. 01 2025 Shattuck Labs shares are trading higher after HC Wainwright & Co upgraded the stock from Neutral to Buy and announced a $6 price target. #tradeideas

0 · Reply

ScreenerIQ Dec. 1 at 4:56 PM

Some of the Top #Stock Gainers Today. Please do your own research. $NFGC $BHC $STTK $LEG $QTTB #StockMarket #investing #trading

1 · Reply

topstockalerts Dec. 1 at 4:19 PM

Top Gainers PT2 $IVDA $MAIA $AGRZ $STTK $AGCC

0 · Reply

topstockalerts Dec. 1 at 3:18 PM

Top Gainers PT2 $IVDA $MAIA $AGRZ $STTK $AGCC

0 · Reply

NyseDayTrader Dec. 1 at 2:31 PM

$STTK

0 · Reply

JarvisFlow Dec. 1 at 12:16 PM

HC Wainwright & Co. has adjusted their stance on Shattuck Labs ( $STTK ), setting the rating to Buy with a target price of 6.

0 · Reply

Iightning Nov. 26 at 5:55 AM

1ightning® Options Trade Alert (Actionable) | Buy $STTK Dec 19 $2 Call | Enter: $0.14 Exit: $0.25 | Profit: 81.68% ROI | https://1ightning.com

0 · Reply

topstockalerts Nov. 26 at 12:35 AM

After Hours Top Gainers PT2 $CETY $STTK $SHMD $BLZE $HKPD

0 · Reply

Iightning Nov. 25 at 4:03 PM

1ightning® Options Trade Alert (Actionable) | Buy $STTK Dec 19 $2 Call | Enter: $0.14 Exit: $0.25 | Profit: 81.68% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 25 at 4:58 AM

1ightning® Options Trade Alert (Actionable) | Buy $STTK Dec 19 $2 Call | Enter: $0.14 Exit: $0.25 | Profit: 81.68% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 22 at 2:08 AM

1ightning® Options Trade Alert (Actionable) | Buy $STTK Dec 19 $2 Call | Enter: $0.29 Exit: $0.49 | Profit: 70.38% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 21 at 5:31 AM

1ightning® Options Trade Alert (Actionable) | Buy $STTK Dec 19 $2 Call | Enter: $0.29 Exit: $0.49 | Profit: 70.38% ROI | https://1ightning.com

0 · Reply

NyseDayTrader Nov. 20 at 1:39 PM

$STTK bought 5k more at $1.95 yesterday. 10 total. I won’t chase. I’ll just ride this position or sell half if it continues to bounce.

0 · Reply

Market Cap	156.93M
Revenue (ttm)	5.72M
Net Income (ttm)	-75.41M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,318.36%
Debt to Equity Ratio	0.00

Volume	576,800
Avg Vol	267,334
Day's Range	N/A - N/A
Shares Out	63.28M
Stochastic %K	97%
Beta	1.70
Analysts	Strong Sell
Price Target	$3.75